Evidence map›Paper›PMID 41202131›Full record

ArticleScience advances2025

Oligo-CALL: A next-generation barcoding platform for studying resistance to targeted therapy.

Yingzhuo Liu, Yi Ban, Dingcheng Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yingzhuo LiuDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA.ORCID 0009-0007-6120-8023
Yi BanDepartment of Medicine, New York University Grossman School of Medicine, 522 First Avenue, New York, NY 10016, USA.ORCID 0000-0002-7644-9686
Dingcheng GaoDepartment of Cardiothoracic Surgery, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA.ORCID 0000-0002-3903-2603

Funding

To study the EMT contributions in tumor metastasis and chemoresistance by using lineage tracing modelsR01CA244413 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GAO, DINGCHENG · 2020 to 2024
$2.4M
NCI NIH HHS R01 CA244413
6 · The paper itself

Abstract

Understanding therapy resistance requires deconvolving heterogeneous cell populations and tracking clonal trajectories. While CRISPR-based cellular barcoding is powerful for lineage tracing, many platforms suffer from low efficiency and limited compatibility with single-cell transcriptomics. We developed Oligo-CALL (Oligonucleotide-inducible CRISPR transcriptional activator-Assisted Lineage Labeling), an advanced barcoding system enabling precise lineage tracing, live clone isolation, and seamless integration with single-cell RNA sequencing. Applied to lung cancer cells treated with a KRAS

Indexed as

Drug Resistance, NeoplasmLung NeoplasmsCell Line, TumorCRISPR-Cas SystemsHumansMolecular Targeted TherapyProto-Oncogene Proteins p21(ras)Single-Cell AnalysisProto-Oncogene Proteins p21(ras)

Identifiers

PMID41202131
PMCPMC12594195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.